TY - JOUR
T1 - Longitudinal Change of DAT SPECT in Parkinson's Disease and Multiple System Atrophy
AU - Sakakibara, Satoko
AU - Hashimoto, Rina
AU - Katayama, Taiji
AU - Kenjyo, Masakuni
AU - Yokokawa, Yuki
AU - Saito, Yufuko
AU - Hirakawa, Akihiro
AU - Ito, Mizuki
AU - Nakamura, Tomohiko
AU - Hara, Kazuhiro
AU - Hashizume, Atsushi
AU - Aiba, Ikuko
AU - Inukai, Akira
AU - Katsuno, Masahisa
N1 - Funding Information:
Tomohiko Nakamura receives a KAKENHI grant from MEXT/JSPS, Japan (No. 16K09713). Ikuko Aiba receives research support from the Research Committee of CNS Degenerative Diseases, the Ministry of Health, Labor and Welfare of Japan and the Japan Agency for Medical Research and Development (AMED). Masahisa Katsuno receives a KAKENHI grant from MEXT/JSPS, Japan (No. 17H04195); grants from the Japan Agency of Medical Research and Development (AMED) (Nos. 17ek0109221h0001, 17dk0207027h0002, 15ek0109025, and 15ek0109165); grants from The Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT); a grant from the Naito Foundation; a grant from The Uehara Memorial Foundation; research grants from Otsuka Pharmaceutical, Nihon Pharmaceutical, Sanofi, Astellas, Sumitomo Dainippon, Pfizer, and Takeda; and speaking fees from Nihon Medi-physics, Daiichi-Sankyo, Sumitomo Dainippon, Takeda, and Tanabe-Mitsubishi.
Funding Information:
This work was supported by a grant from Ministry of Health, Labour and Welfare, Japan, and a grant from the Naito Foundation. There were no other funding sources, and the investigators had sole discretion over study design, collection, analysis, and interpretation of data, writing of the report, and the decision to submit it for publication.
Publisher Copyright:
© 2020-IOS Press and the authors. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Background: Both Parkinson's disease (PD) and multiple system atrophy (MSA) are neurodegenerative disorder affecting striatonigral system. Although various lines of evidence demonstrate that dopaminergic neuron degeneration emerges before the onset of motor symptoms in PD, preclinical/prodromal progression of neurodegeneration is far less understood in MSA. Objective: The aim of this study was to clarify the difference in the progression of dopaminergic degeneration in MSA and PD using dopamine transporter single-photon emission computed tomography (DAT SPECT). Methods: We analyzed longitudinal data of the specific binding ratio (SBR), a measure of striatal radiotracer uptake, in DAT SPECT from 7 patients with MSA-C, 5 patients with MSA-P, and 18 patients with PD. We performed 2.7±0.7 scans with an interval of 9.85±6.00 months for MSA and 2 scans with an interval of 2.16±0.16 years for PD. Results: The rate of SBR decline was faster in both subtypes of MSA compared with PD, but the value was similar between MSA-P and MSA-C. The estimated SBR at the onset of initial motor symptoms was lower in PD and MSA-P than in MSA-C, especially in the predominantly affected side. SBR of the predominantly affected side starts to decrease before the onset of motor symptoms in PD and MSA-P, whereas the initiation of SBR decline is around the onset in MSA-C individuals. The decline of SBR in the less affected side was not clearly shown before the onset in MSA-P or MSA-C. Conclusions: Our results suggest that the SBR in DAT SPECT analysis is an important pathophysiological marker reflecting the disease-and subtype-specific progression of dopaminergic degeneration in MSA and PD.
AB - Background: Both Parkinson's disease (PD) and multiple system atrophy (MSA) are neurodegenerative disorder affecting striatonigral system. Although various lines of evidence demonstrate that dopaminergic neuron degeneration emerges before the onset of motor symptoms in PD, preclinical/prodromal progression of neurodegeneration is far less understood in MSA. Objective: The aim of this study was to clarify the difference in the progression of dopaminergic degeneration in MSA and PD using dopamine transporter single-photon emission computed tomography (DAT SPECT). Methods: We analyzed longitudinal data of the specific binding ratio (SBR), a measure of striatal radiotracer uptake, in DAT SPECT from 7 patients with MSA-C, 5 patients with MSA-P, and 18 patients with PD. We performed 2.7±0.7 scans with an interval of 9.85±6.00 months for MSA and 2 scans with an interval of 2.16±0.16 years for PD. Results: The rate of SBR decline was faster in both subtypes of MSA compared with PD, but the value was similar between MSA-P and MSA-C. The estimated SBR at the onset of initial motor symptoms was lower in PD and MSA-P than in MSA-C, especially in the predominantly affected side. SBR of the predominantly affected side starts to decrease before the onset of motor symptoms in PD and MSA-P, whereas the initiation of SBR decline is around the onset in MSA-C individuals. The decline of SBR in the less affected side was not clearly shown before the onset in MSA-P or MSA-C. Conclusions: Our results suggest that the SBR in DAT SPECT analysis is an important pathophysiological marker reflecting the disease-and subtype-specific progression of dopaminergic degeneration in MSA and PD.
UR - http://www.scopus.com/inward/record.url?scp=85078408432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078408432&partnerID=8YFLogxK
U2 - 10.3233/JPD-191710
DO - 10.3233/JPD-191710
M3 - Article
C2 - 31707374
AN - SCOPUS:85078408432
VL - 10
SP - 123
EP - 130
JO - Journal of Parkinson's Disease
JF - Journal of Parkinson's Disease
SN - 1877-7171
IS - 1
ER -